SCHEMBL124562

SCHEMBL124562

CC1=CC(=O)OC1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11800450 0.75
SCHEMBL5316374 0.72
SCHEMBL14326907 0.72
SCHEMBL5315347 0.72
SCHEMBL8709485 0.72
SCHEMBL16644735 0.72 POLB (0.35)
SCHEMBL8371681 0.70 ELANE (0.31)
SCHEMBL218538 0.67 TSHR (0.36)
SCHEMBL13442999 0.66 ELANE (0.33)
SCHEMBL4651121 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197381-A1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-19 US disclosed
US-12247021-B2 Substituted tetrahydrofurans as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-03-11 US disclosed
EP-4506001-A2 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2025-02-12 EP disclosed
US-20240391907-A1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-11-28 US disclosed
EP-4069691-B1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-09-18 EP disclosed
EP-4347032-A1 SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Vertex Pharmaceuticals Incorporated (US) 2024-04-10 EP disclosed
US-11919887-B2 Substituted tetrahydrofurans as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-03-05 US disclosed
US-11834441-B2 Substituted tetrahydrofurans as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-12-05 US disclosed
US-11834441-B2 Substituted tetrahydrofurans as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-12-05 US disclosed
US-11834441-B2 Substituted tetrahydrofurans as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-12-05 US disclosed
EP-1937264-B1 COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE MERCK SHARP & DOHME (US) 2011-06-08 EP disclosed
US-20090270406-A1 Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence MERCK SHARP & DOHME CORP. 2009-10-29 US disclosed
US-20090270406-A1 Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence MERCK SHARP & DOHME CORP. 2009-10-29 US disclosed
US-7468437-B2 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2008-12-23 US disclosed
US-7468437-B2 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2008-12-23 US disclosed
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2008-01-03 US disclosed
WO-2007044296-A2 COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE MERCK & CO., INC. (US) 2007-04-19 WO disclosed
US-20070043015-A1 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2007-02-22 US disclosed
US-20070043015-A1 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2007-02-22 US disclosed
EP-0547708-B1 Saccharin derivative proteolytic enzyme inhibitors SANOFI SYNTHELABO (FR) 2003-02-26 EP disclosed